pyruvaldehyde has been researched along with canagliflozin in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nomiyama, T | 1 |
1 other study(ies) available for pyruvaldehyde and canagliflozin
| Article | Year |
|---|---|
Can SGLT2 Inhibitor be Used for Diabetes Mellitus or Vascular Diseases?
Topics: Animals; Atherosclerosis; Blood Glucose; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus; Glucose; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Inflammation; Mice; Pyruvaldehyde; Quality of Life; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vascular Diseases | 2020 |